The Journal of Urology
Volume 176, Issue 4 , Pages 1642-1647, October 2006

Vitamins C and K3 Sensitize Human Urothelial Tumors to Gemcitabine

  • Wassim Kassouf

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
  • ,
  • Ralph Highshaw

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
  • ,
  • Gina M. Nelkin

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
  • ,
  • Colin P. Dinney

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with AstraZeneca, GlaxoSmithKline, National Cancer Institute, Canji/Schering-Plough and Abbott/Vysis.
  • ,
  • Ashish M. Kamat

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Healthgate, Pharmacia and Abbott.
    • Corresponding Author InformationCorrespondence and requests for reprints: Departments of Urology and Cancer Biology, Unit 1373, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (telephone: 713-792-3250; FAX: 713-794-4824)

Received 24 September 2005

Purpose

We evaluated the antitumor effects of vitamins C and K3 for human urothelial carcinoma and the potential use of the combination of vitamins C plus K3 as a sensitizing agent for conventional chemotherapy for urothelial carcinoma.

Materials and Methods

The antiproliferative and apoptotic effects of vitamin C alone, vitamin K3 alone, vitamins C plus K3, gemcitabine alone and gemcitabine plus vitamins C plus K3 were assessed in vitro by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, propidium iodide staining and flow cytometry. For in vivo studies we implanted UMUC-14 tumorigenic urothelial carcinoma cells into the subcutis of nude mice. One week later we treated 10 mice each with saline (control), vitamins C plus K3, gemcitabine or gemcitabine plus vitamins C plus K3. Treatment was continued for 4 weeks, followed by necropsy. Tumor volume was measured and tumor kinetics were established. Apoptosis and proliferation were evaluated in tumor sections using immunohistochemistry and TUNEL assay.

Results

Vitamins C plus K3 induced cytostasis and caused apoptosis to a greater degree than either vitamin alone (p <0.05). Vitamins C plus K3 also substantially augmented the effects of gemcitabine in vitro. There were 32.3% apoptosis with gemcitabine plus vitamins C plus K3, 5.3% with gemcitabine alone and 15.8% with vitamins C plus K3 alone (p <0.05). In vivo tumor growth was substantially inhibited by gemcitabine plus vitamins C plus K3 compared with that in the control or for either agent alone. Mean tumor weight and growth rate in the gemcitabine plus vitamins C plus K3 group (237 mg and 11.3 mm3 daily) were decreased compared with those in the control (530 mg and 34.3 mm3 daily), and those for vitamins C plus K3 alone (490 mg and 25.2 mm3 daily) and gemcitabine alone (400 mg and 21.3 mm3 daily) (p <0.05).

Conclusions

Vitamins C and K3 have significant antiproliferative and apoptotic effects when used in combination. This combination enhances the efficacy of gemcitabine against bladder cancer in vivo.

Key Words:  bladder , bladder neoplasms , urothelium , ascorbic acid , vitamin K3

Abbreviations and Acronyms:  CK3, combination of vitamins C and K3 , Gem, gemcitabine , IHC, immunohistochemical analysis , MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide , PBS, phosphate buffered saline , PCNA, proliferating cell nuclear antigen , UC, urothelial carcinoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by SPORE Developmental Research Grant 5P50CA091846-03.

PII: S0022-5347(06)01418-2

doi:10.1016/j.juro.2006.06.042

The Journal of Urology
Volume 176, Issue 4 , Pages 1642-1647, October 2006